Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBCBS Nebraska GI Pathogen Panel Coverage Update | …
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - NebraskaPolicy V.49

    Outpatient Gastrointestinal Pathogen Panel

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Nebraska Policy V.49 alerts

    Get alerted when Policy V.49 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and medical necessity for nucleic acid–based gastrointestinal (GI) pathogen panel testing in outpatient and inpatient settings for BCBSNE members, with special coverage provisions for immunocompromised outpatients.

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyOutpatient Gastrointestinal Pathogen Panel
    Policy CodePolicy V.49
    Change TypeCoverage and coding updates
    Effective DateJul 1, 2026
    Last ReviewDec 1, 2025
    Next Review DateAug 5, 2026
    Key ActionSupport outpatient GI panel claims for immunocompromised patients with documentation and expect claim review per policy.
    SourceLink
    POLICY UPDATE CHANGES

    Policy updated to allow outpatient GI panel testing for immunocompromised individuals.

    New CPT/PLA code 0369U was added to the codes list (effective 04/01/2023).

    coveredInpatient coverage

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    coveredOutpatient — immunocompromised
    investigationalOutpatient — non-immunocompromised
    0097U,0369U,87505-7Procedure codes referenced

    Coverage Criteria for GI Pathogen Panels

    Inpatient coverage

    Covered (scientifically validated) in the inpatient setting

    Inpatient setting: Use of nucleic acid testing using a direct or amplified probe technique with or without quantification of viral load for Gastrointestinal (GI) Pathogen Panel is scientifically validated when performed in the inpatient setting.

    Outpatient — Non-immunocompromised / Investigational

    Not covered (considered investigational) when ANY of the following apply

    Outpatient non-immunocompromised: Outpatient GI Pathogen Panel ordered for patients who are not immunocompromised or for routine outpatient indications without documented high-risk status.

    Policy states GI Pathogen Panel for all other outpatient indications is investigational and not medically necessary.

    When a specific pathogen is clinically suspected, the policy recommends ordering an individual (single‑plex) diagnostic test rather than a broad multiplex GI pathogen panel. The source document states that, in most instances, individual tests could be ordered when a particular organism is suspected and that broad panels are most appropriate only for a small, not‑well‑defined subset of patients with unusual presentations. Providers should therefore consider targeted testing first and reserve multiplex panels for cases where multiple pathogens are reasonably suspected or when clinical circumstances (for example, atypical presentation) justify simultaneous multi‑target testing.

    GI Pathogen Panel testing performed in the outpatient setting for indications other than immunocompromised patients is considered investigational and therefore not medically necessary. The policy explicitly limits outpatient coverage to patients who are immunocompromised (examples provided include transplant recipients, patients receiving cancer treatment, persons with HIV, patients with Crohn's disease, or patients on immunosuppressive therapy).

    Indications Considered Medically Necessary

    Diagnostic testing for signs and/or symptoms of gastroenteritis in inpatients; diagnostic testing in outpatients who are immunocompromised.

    Diagnostic testing for signs and/or symptoms of gastroenteritis in inpatients; diagnostic testing in outpatients who are immunocompromised.

    Clinical indication: Patient has signs and/or symptoms of gastroenteritis and testing is intended for diagnostic evaluation.

    Order should document signs/symptoms of gastroenteritis; when a specific pathogen is suspected, single-target testing may be preferable.

    Procedure and PLA Codes

    PLA codes listedCPT-PLA
    0097UGI PTHGN MULT REV TRANS& PRB TECH 22 TRGT
    0369UIADNA GI PTHGN 31ORG& ID 21 ARG MULT AMP PRB TQ
    CPT codes listedCPT
    87505INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); GASTROINTESTINAL PATHOGEN, INCLUDES MULTIPLEX REVERSE TRANSCRIPTION, 3-5 TARGETS
    87506INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); GASTROINTESTINAL PATHOGEN, INCLUDES MULTIPLEX REVERSE TRANSCRIPTION, 6-11 TARGETS
    87507INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); GASTROINTESTINAL PATHOGEN, INCLUDES MULTIPLEX REVERSE TRANSCRIPTION, 12-25 TARGETS
    Panel target count thresholds
    CPT 87505Gastrointestinal pathogen nucleic acid detection — multiplex reverse transcription/amplified probe technique for 3–5 targets
    CPT 87506Gastrointestinal pathogen nucleic acid detection — multiplex reverse transcription/amplified probe technique for 6–11 targets
    CPT 87507Gastrointestinal pathogen nucleic acid detection — multiplex reverse transcription/amplified probe technique for 12–25 targets
    Specific PLA panel sizes
    PLA 0097UGastrointestinal pathogen, multiplex reverse transcription and multiplex amplified probe technique — 22 targets
    PLA 0369UInfectious agent detection by nucleic acid (DNA and RNA) for gastrointestinal pathogens — 31 organisms plus identification of 21 antibiotic-resistance genes (multiplex amplified probe technique)

    Provider Documentation and Authorization Expectations

    Prior Authorization

    Prior authorization / claim review expectation for outpatient panels

    Testing for outpatient GI pathogen panels will be subject to claim review and must be supported by clinical documentation that meets the policy criteria; outpatient panels are allowable only for immunocompromised patients.

    • Providers should expect claims to be reviewed against the policy and listed procedure codes (0097U, 0369U, 87505, 87506, 87507).
    Step Therapy

    Consider single-pathogen testing first

    If a specific pathogen is suspected based on clinical presentation, order a single-target (individual) test instead of a broad multiplex GI panel when clinically appropriate.

    • The policy notes individual tests can be ordered in most instances when a specific agent is suspected.

    Ordering Requirements

    Billing Rule

    Ordering requirements — document gastroenteritis and prefer single-target tests when appropriate

    Orders must document clinical signs or symptoms of gastroenteritis; when a specific pathogen is suspected, prefer single-target tests over multiplex panels and use the policy-listed CPT/PLA codes for multiplex testing.

    • Document signs/symptoms of gastroenteritis in the order.
    • If ordering a multiplex panel, reference the appropriate code(s) (examples: 0097U, 0369U, 87505–87507) as listed in the policy.
    • Prefer single-plex testing when a specific pathogen is suspected, per policy guidance.

    Frequency Limits

    Frequency limits (policy)No specific frequency limits are defined in the policy text provided.
    Frequency limit periodNot specified
    NotesPolicy does not list repeat testing intervals or units; clinical judgment and ordering requirements apply.

    Not Covered / Investigational

    Outpatient gastrointestinal pathogen panel testing for patients who are not immunocompromised is considered investigational and is therefore not covered. The policy explains that while multiplex NAAT panels have high sensitivity and can detect bacterial and viral pathogens more rapidly than conventional methods, evidence is insufficient to demonstrate improved health outcomes for general outpatient populations, and routine outpatient use (outside of the immunocompromised subgroup) is a trigger for denial.

    Definitions and Test Descriptions

    Multiplex GI PCR/NAAT panel definition
    DefinitionA nucleic acid amplified probe technique that detects multiple bacterial, viral, and parasitic gastrointestinal pathogens simultaneously from stool specimens.
    PurposeProvides high-sensitivity, rapid detection of multiple GI pathogens to aid diagnosis, early treatment, and infection control, particularly in high-risk patients.
    Technique examplesIncludes multiplex reverse transcription and multiplex amplified probe methods as described for PLA and CPT codes.
    Example code descriptors
    0097U descriptorGI PTHGN MULT REV TRANS & PRB TECH — multiplex reverse transcription and amplified probe technique for 22 targets (full target list provided in code description).
    0369U descriptor

    Background

    Nucleic acid–based multiplex gastrointestinal pathogen panels use amplified probe techniques to detect nucleic acids (DNA or RNA) from bacterial, viral, and parasitic organisms in stool specimens. These assays identify pathogens directly by their genetic material rather than by culture, microscopy, antigen or toxin assays, or single‑plex PCR alone. Multiplex panels can provide higher sensitivity and more rapid turnaround compared with many conventional stool studies, which may facilitate earlier targeted therapy and infection‑control measures—particularly in high‑risk or immunocompromised patients—but the evidence is insufficient to demonstrate improved health outcomes for routine outpatient use.

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyOutpatient Gastrointestinal Pathogen Panel
    Policy CodePolicy V.49
    Change TypeCoverage and coding updates
    Effective DateJul 1, 2026
    Last ReviewDec 1, 2025
    Next Review DateAug 5, 2026
    Key ActionSupport outpatient GI panel claims for immunocompromised patients with documentation and expect claim review per policy.
    SourceLink
    On This Page
    Coverage Criteria for GI Pathogen PanelsIndications Considered Medically NecessaryProcedure and PLA CodesProvider Documentation and Authorization ExpectationsOrdering RequirementsFrequency LimitsNot Covered / InvestigationalDefinitions and Test DescriptionsBackground
    Documentation Required

    Required clinical documentation

    Document signs and/or symptoms of gastroenteritis in the medical record; for outpatient panel testing, also document evidence that the patient is immunocompromised (examples provided in policy).

    • Examples of immunocompromised status include transplant recipients, patients receiving cancer treatment, persons with HIV, patients with Crohn's disease, or patients on immunosuppressive therapy for rheumatoid arthritis.
    • Documentation should support the high-risk status referenced by the policy; the list of examples is not all-inclusive.
    Denial Risk

    Investigational outpatient indications — denial risk

    Outpatient GI pathogen panel testing for indications other than immunocompromised patients is considered investigational and may be denied.

    • Routine outpatient testing in patients who are not immunocompromised is not supported by the policy and is a trigger for denial.
    IADNA GI PTHGN 31ORG & ID 21 ARG MULT AMP PRB TQ — detection of 31 organisms and identification of 21 associated antibiotic-resistance genes via multiplex amplified probe technique.
    87505-87507 descriptorsCPT codes 87505–87507 correspond to nucleic acid detection for GI pathogens with increasing panel sizes (87505: 3–5 targets; 87506: 6–11 targets; 87507: 12–25 targets).